{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T18:18:14Z","timestamp":1780683494936,"version":"3.54.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2019,10,15]],"date-time":"2019-10-15T00:00:00Z","timestamp":1571097600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,10,15]],"date-time":"2019-10-15T00:00:00Z","timestamp":1571097600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1007\/s10620-019-05883-1","type":"journal-article","created":{"date-parts":[[2019,10,15]],"date-time":"2019-10-15T11:26:43Z","timestamp":1571138803000},"page":"1512-1519","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Usefulness of Controlled Attenuation Parameter in Detecting and Monitoring Hepatic Steatosis with MRI-PDFF as Reference"],"prefix":"10.1007","volume":"65","author":[{"given":"Jing-Houng","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsin-You","family":"Ou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Hao","family":"Yen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chien-Hung","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng-Nan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,10,15]]},"reference":[{"key":"5883_CR1","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","volume":"64","author":"ZM Younossi","year":"2016","unstructured":"Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease- meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64:73\u201384.","journal-title":"Hepatology"},{"key":"5883_CR2","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1111\/jgh.13857","volume":"33","author":"VW Wong","year":"2018","unstructured":"Wong VW, Chan WK, Chitturi S, et al. Asia-Pacific Working Party on Nonalcoholic Fatty Liver Disease guidelines 2017-Part 1: definition, risk factors and assessment. J Gastroenterol Hepatol. 2018;33:70\u201385.","journal-title":"J Gastroenterol Hepatol"},{"key":"5883_CR3","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1002\/hep.29367","volume":"67","author":"N Chalasani","year":"2018","unstructured":"Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67:328\u2013357.","journal-title":"Hepatology"},{"key":"5883_CR4","first-page":"1388","volume":"64","author":"European Association for the Study of the Liver (EASL)","year":"2016","unstructured":"European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL-EASD-EASO clinical practice guidelines for the management of nonalcoholic fatty liver disease. J Hepatol. 2016;64:1388\u20131402.","journal-title":"J Hepatol"},{"key":"5883_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jhep.2008.10.014","volume":"50","author":"P Bedossa","year":"2009","unstructured":"Bedossa P, Carrat F. Liver biopsy: the best, not the gold standard. J Hepatol. 2009;50:1\u20133.","journal-title":"J Hepatol"},{"key":"5883_CR6","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1016\/j.jhep.2016.06.005","volume":"65","author":"PS Dulai","year":"2016","unstructured":"Dulai PS, Sirlin CB, Loomba R. MRI and MRE for non-invasive quantitative assessment of hepatic steatosis and fibrosis in NAFLD and NASH: clinical trials to clinical practice. J Hepatol. 2016;65:1006\u20131016.","journal-title":"J Hepatol"},{"key":"5883_CR7","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1016\/j.ultrasmedbio.2010.07.005","volume":"36","author":"M Sasso","year":"2010","unstructured":"Sasso M, Beaugrand M, de Ledinghen V, et al. Controlled attenuation parameter (CAP): a novel VCTE\u2122 guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes. Ultrasound Med Biol. 2010;36:1825\u20131835.","journal-title":"Ultrasound Med Biol"},{"key":"5883_CR8","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1111\/j.1365-2893.2011.01534.x","volume":"19","author":"M Sasso","year":"2012","unstructured":"Sasso M, Tengher-Barna I, Ziol M, et al. Novel controlled attenuation parameter for noninvasive assessment of steatosis using Fibroscan(\u00ae): validation in chronic hepatitis C. J Viral Hepat. 2012;19:244\u2013253.","journal-title":"J Viral Hepat"},{"key":"5883_CR9","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1002\/hep.29639","volume":"67","author":"C Caussy","year":"2018","unstructured":"Caussy C, Alquiraish MH, Nguyen P, et al. Optimal threshold of controlled attenuation parameter with MRI-PDFF as the gold standard for the detection of hepatic steatosis. Hepatology. 2018;67:1348\u20131359.","journal-title":"Hepatology"},{"key":"5883_CR10","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1016\/j.ultrasmedbio.2015.03.007","volume":"41","author":"G Ferraioli","year":"2015","unstructured":"Ferraioli G, Filice C, Castera L, et al. WFUMB guidelines and recommendations for clinical use of ultrasound elastography: Part 3: liver. Ultrasound Med Biol. 2015;41:1161\u20131179.","journal-title":"Ultrasound Med Biol"},{"key":"5883_CR11","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1002\/jmri.22514","volume":"33","author":"CD Hines","year":"2011","unstructured":"Hines CD, Frydrychowicz A, Hamilton G, et al. T(1) independent, T(2) (*) corrected chemical shift based fat-water separation with multi-peak fat spectral modeling is an accurate and precise measure of hepatic steatosis. J Magn Reson Imaging. 2011;33:873\u2013881.","journal-title":"J Magn Reson Imaging"},{"key":"5883_CR12","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1002\/hep.26455","volume":"58","author":"M Noureddin","year":"2013","unstructured":"Noureddin M, Lam J, Peterson MR, et al. Utility of magnetic resonance imaging versus histology for quantifying changes in liver fat in nonalcoholic fatty liver disease trials. Hepatology. 2013;58:1930\u20131940.","journal-title":"Hepatology"},{"key":"5883_CR13","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1053\/j.gastro.2015.11.048","volume":"150","author":"K Imajo","year":"2016","unstructured":"Imajo K, Kessoku T, Honda Y, et al. Magnetic resonance imaging more accurately classifies steatosis and fibrosis in patients with nonalcoholic fatty liver disease than transient elastography. Gastroenterology. 2016;150:626\u2013637.","journal-title":"Gastroenterology"},{"key":"5883_CR14","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/j.jhep.2016.12.022","volume":"66","author":"T Karlas","year":"2017","unstructured":"Karlas T, Petroff D, Sasso M, et al. Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis. J Hepatol. 2017;66:1022\u20131030.","journal-title":"J Hepatol"},{"key":"5883_CR15","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1111\/jgh.12519","volume":"29","author":"KQ Shi","year":"2014","unstructured":"Shi KQ, Tang JZ, Zhu XL, et al. Controlled attenuation parameter for the detection of steatosis severity in chronic liver disease: a meta-analysis of diagnostic accuracy. J Gastroenterol Hepatol. 2014;29:1149\u20131158.","journal-title":"J Gastroenterol Hepatol"},{"key":"5883_CR16","first-page":"17654","volume":"8","author":"Y Wang","year":"2015","unstructured":"Wang Y, Fan Q, Wang T, Wen J, Wang H, Zhang T. Controlled attenuation parameter for assessment of hepatic steatosis grades: a diagnostic meta-analysis. Int J Clin Exp Med. 2015;8:17654\u201317663.","journal-title":"Int J Clin Exp Med"},{"key":"5883_CR17","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.cgh.2018.04.043","volume":"17","author":"MS Siddiqui","year":"2019","unstructured":"Siddiqui MS, Vuppalanchi R, Van Natta ML, et al. Vibration-controlled transient elastography to assess fibrosis and steatosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2019;17:156\u2013163.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"5883_CR18","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.jhep.2017.05.005","volume":"67","author":"VW Wong","year":"2017","unstructured":"Wong VW, Petta S, Hiriart JB, et al. Validity criteria for the diagnosis of fatty liver by M probe-based controlled attenuation parameter. J Hepatol. 2017;67:577\u2013584.","journal-title":"J Hepatol"},{"key":"5883_CR19","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1053\/j.gastro.2016.02.086","volume":"151","author":"T Karlas","year":"2016","unstructured":"Karlas T, Petroff D. Is magnetic resonance imaging really more accurate for classifying steatosis than controlled attenuation parameter? Gastroenterology. 2016;151:374\u2013375.","journal-title":"Gastroenterology"},{"key":"5883_CR20","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1038\/nrgastro.2018.10","volume":"15","author":"EB Tapper","year":"2018","unstructured":"Tapper EB, Loomba R. Noninvasive imaging biomarker assessment of liver fibrosis by elastography in NAFLD. Nat Rev Gastroenterol Hepatol. 2018;15:274\u2013282.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"5883_CR21","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1136\/gutjnl-2015-309265","volume":"65","author":"R Kwok","year":"2016","unstructured":"Kwok R, Choi KC, Wong GL, et al. Screening diabetic patients for nonalcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: a prospective cohort study. Gut. 2016;65:1359\u20131368.","journal-title":"Gut"},{"key":"5883_CR22","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1002\/hep.25731","volume":"56","author":"TA Le","year":"2012","unstructured":"Le TA, Chen J, Changchien C, et al. Effect of colesevelam on liver fat quantified by magnetic resonance in nonalcoholic steatohepatitis: a randomized controlled trial. Hepatology. 2012;56:922\u2013932.","journal-title":"Hepatology"},{"key":"5883_CR23","doi-asserted-by":"publisher","first-page":"175","DOI":"10.15403\/jgld.2014.1121.252.cap","volume":"25","author":"I Papapostoli","year":"2016","unstructured":"Papapostoli I, Lammert F, Stokes CS. Effect of short-term vitamin D correction on hepatic steatosis as quantified by controlled attenuation parameter (CAP). J Gastrointestin Liver Dis. 2016;25:175\u2013181.","journal-title":"J Gastrointestin Liver Dis"},{"key":"5883_CR24","doi-asserted-by":"publisher","first-page":"e176","DOI":"10.1038\/ctg.2016.28","volume":"7","author":"A Arslanow","year":"2016","unstructured":"Arslanow A, Teutsch M, Walle H, Gr\u00fcnhage F, Lammert F, Stokes CS. Short-term hypocaloric high-fiber and high-protein diet improves hepatic steatosis assessed by controlled attenuation parameter. Clin Transl Gastroenterol. 2016;7:e176.","journal-title":"Clin Transl Gastroenterol"},{"key":"5883_CR25","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1002\/jmv.24950","volume":"90","author":"N Ogasawara","year":"2018","unstructured":"Ogasawara N, Kobayashi M, Akuta N, et al. Serial changes in liver stiffness and controlled attenuation parameter following direct-acting antiviral therapy against hepatitis C virus genotype 1b. J Med Virol. 2018;90:313\u2013319.","journal-title":"J Med Virol"},{"key":"5883_CR26","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1111\/dom.13520","volume":"21","author":"M Shimizu","year":"2019","unstructured":"Shimizu M, Suzuki K, Kato K, et al. Evaluation of the effects of dapagliflozin, an SGLT2 inhibitor, on hepatic steatosis and fibrosis by transient elastography in patients with type 2 diabetes and nonalcoholic fatty liver disease. Diabetes Obes Metab. 2019;21:285\u2013292.","journal-title":"Diabetes Obes Metab"},{"key":"5883_CR27","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1007\/s10620-017-4638-3","volume":"62","author":"V de L\u00e9dinghen","year":"2017","unstructured":"de L\u00e9dinghen V, Hiriart JB, Vergniol J, Merrouche W, Bedossa P, Paradis V. Controlled attenuation parameter (CAP) with the XL probe of the Fibroscan\u00ae: a comparative study with the M probe and liver biopsy. Dig Dis Sci. 2017;62:2569\u20132577.\n https:\/\/doi.org\/10.1007\/s10620-017-4638-3","journal-title":"Dig Dis Sci"},{"key":"5883_CR28","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1111\/jgh.14150","volume":"33","author":"WK Chan","year":"2018","unstructured":"Chan WK, Nik Mustapha NR, Mahadeva S, Wong VW, Cheng JY, Wong GL. Can the same controlled attenuation parameter cut-offs be used for M and XL probes for diagnosing hepatic steatosis? J Gastroenterol Hepatol. 2018;33:1787\u20131794.","journal-title":"J Gastroenterol Hepatol"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-019-05883-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10620-019-05883-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-019-05883-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,13]],"date-time":"2020-10-13T23:34:22Z","timestamp":1602632062000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10620-019-05883-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,15]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["5883"],"URL":"https:\/\/doi.org\/10.1007\/s10620-019-05883-1","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,15]]},"assertion":[{"value":"11 December 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"All authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}